Arrowhead Pharmaceuticals issued $700,000,000 of 0.00% Convertible Senior Notes due 2032. These unsecured senior notes carry no regular interest and mature on January 15, 2032, with noteholders able to convert earlier under specified conditions and freely from October 15, 2031 until shortly before maturity.
The initial conversion rate is 11.4844 shares per $1,000 principal amount, implying an initial conversion price of about $87.07 per share, subject to customary adjustments and potential increases after certain make‑whole events. Arrowhead may redeem the notes on or after January 16, 2029 if its share price exceeds 130% of the conversion price for defined trading periods, and holders can require repurchase after specified fundamental changes.
In connection with the offering, Arrowhead entered into capped call transactions that cover the shares underlying the notes. The capped calls cost approximately $47.9 million and have an initial cap price of about $119.33 per share, which is described as an 85.0% premium to the public offering price in a concurrent equity offering, aiming to limit dilution and/or offset cash paid above principal on conversion.
Arrowhead Pharmaceuticals is raising capital through an equity offering and a convertible notes sale. The company agreed to sell 3,100,776 shares of common stock at $64.50 per share and, for certain investors, pre-funded warrants to purchase up to 1,550,387 shares at $64.499 per warrant. Underwriters also exercised a 30-day option for an additional 456,116 shares.
The equity transactions are expected to generate net proceeds of approximately $216.6 million. Arrowhead is also issuing $625,000,000 of 0.00% convertible senior notes due 2032, plus an additional $75,000,000 option that underwriters exercised in full, with expected net proceeds of about $681.3 million. Both offerings are made under an automatic shelf registration statement and are expected to close in January 2026, subject to customary conditions.
Arrowhead Pharmaceuticals, Inc. is offering 1,550,389 shares of common stock and pre-funded warrants to purchase 1,550,387 shares of common stock at $64.50 per share and $64.499 per pre-funded warrant, for total gross proceeds of about $199.998 million. Net proceeds from this equity offering are estimated at approximately $188.3 million, or $216.6 million if the underwriters fully exercise their 465,116-share option. As of September 30, 2025, Arrowhead had 135,701,794 shares of common stock outstanding. Concurrently, the company is separately offering 0.00% convertible senior notes due 2032 with an initial aggregate principal amount of $625 million. Arrowhead plans to use the equity and note proceeds, after funding capped call transactions, for general corporate purposes including R&D, clinical trials, commercialization of REDEMPLO and other late-stage products, and potentially to prepay amounts under its 15.0% Credit Facility, which together with existing cash is expected to fund operations into fiscal year 2029.
Arrowhead Pharmaceuticals, Inc. is offering $625,000,000 aggregate principal amount of 0.00% convertible senior notes due 2032, with an additional $75,000,000 available to underwriters to cover over-allotments. The notes pay no regular interest, are senior unsecured obligations, and are convertible at an initial rate of 11.4844 shares per $1,000 principal amount, equal to an initial conversion price of approximately $87.07 per share, subject to customary adjustments.
Conversion is allowed only upon specified stock-price, trading-price, corporate event, redemption and time-based triggers, and Arrowhead may settle conversions in cash, stock or a combination. The notes are redeemable at Arrowhead’s option from January 16, 2029 if the common stock trades above 130% of the conversion price, and holders can require cash repurchase upon certain fundamental changes. The notes rank equally with other senior unsecured debt, are effectively subordinated to secured debt and structurally subordinated to subsidiary liabilities.
Concurrently, Arrowhead is conducting an equity offering of 3,100,776 common shares (or pre-funded warrants to purchase 1,550,387 shares) plus an underwriter option for 465,116 additional shares. Estimated net proceeds from the notes are about $608.2 million, including approximately $42.8 million for capped call transactions, with remaining proceeds, together with an estimated $188.3 million from the concurrent equity offering and existing liquidity, intended for general corporate purposes and potential prepayment of a 15.0% Credit Facility maturing in 2031. Key risks highlight the additional leverage, subordination of the notes, absence of regular interest, refinancing and repurchase obligations, market and liquidity risks for the notes, tax complexities around conversion adjustments, and counterparty risk and complexity related to the capped call transactions.
Arrowhead Pharmaceuticals Chief Medical Officer reports stock award. On 01/06/2026, Chief Medical Officer James C. Hamilton was granted 75,000 shares of Arrowhead Pharmaceuticals common stock underlying restricted stock units at a price of $0 per share.
These restricted stock units will vest in four equal annual installments. Following this award, Hamilton beneficially owned 246,958 shares of common stock, including previously reported shares underlying restricted stock units, some of which remain subject to vesting conditions.
Arrowhead Pharmaceuticals’ Chief Financial Officer Daniel Joseph Apel reported an equity award of company stock. On January 6, 2026, he acquired 75,000 shares of common stock at a price of $0 per share, representing shares underlying restricted stock units. These RSUs will vest in four equal annual installments, meaning portions of the award become fully owned over four years if conditions are met. Following this grant, Apel beneficially owns 176,200 shares of common stock, which includes previously reported RSU-based holdings, some of which remain subject to vesting conditions.
Arrowhead Pharmaceuticals COO Patrick O'Brien reported several stock gifts and a new equity award. On January 6, 2026, he made multiple transactions coded "G" that transferred a total of 2,500 shares of common stock as a gift to relatives at a price of $0 per share, reducing his holdings stepwise in small blocks.
On the same date, he acquired 75,000 shares of common stock coded "A", representing shares underlying restricted stock units (RSUs) that will vest in four equal annual installments. After these transactions, he beneficially owned 547,408 shares of Arrowhead common stock directly, which includes previously reported RSUs, some of which remain subject to vesting conditions.
Arrowhead Pharmaceuticals is offering $200,000,000 of common stock in a primary public offering. The company has granted underwriters a 30-day option to buy up to an additional $30,000,000 of stock. Its shares trade on the Nasdaq Global Select Market under the symbol ARWR and it had 135,702,000 shares outstanding as of September 30, 2025.
Arrowhead is concurrently marketing $500,000,000 of convertible senior notes due 2032, with a $75,000,000 over-allotment option for the note underwriters. Together with existing cash, cash equivalents and short-term investments, the net proceeds from the equity and note offerings are expected to fund planned operations into fiscal year 2029, including commercialization of REDEMPLO, research and development, clinical trials and potential prepayment of a 15.0% term loan under its Credit Facility.
The company highlights that new investors may experience immediate and substantial dilution and that future equity or convertible debt issuance, including conversion of the notes, could further dilute existing stockholders and pressure the share price. The filing also details risks linked to higher leverage from the new notes, potential volatility from hedging and capped call transactions, and obligations to repurchase or settle the notes in cash or stock upon conversion or certain corporate events.
Arrowhead Pharmaceuticals is offering $500,000,000 of convertible senior notes due 2032, with underwriters holding an option to buy up to an additional $75,000,000 of notes. The notes pay semi-annual cash interest, mature on January 15, 2032, and are convertible into cash, Arrowhead common stock, or a combination, at the company’s election, subject to specified stock price and trading conditions, corporate events, redemption, or during a final free-conversion period before maturity.
The notes are senior unsecured obligations, ranking equally with other senior unsecured debt and effectively subordinated to secured borrowings and subsidiary liabilities. Concurrently, Arrowhead is separately offering $200,000,000 of common stock, plus a $30,000,000 over-allotment option. Net proceeds from the notes will fund capped call transactions, general corporate uses including R&D, commercialization and potential late-stage launches, and may be used in part to prepay a 15.0% Credit Facility, with the combined financings expected to fund operations into fiscal 2029.
Arrowhead Pharmaceuticals reported interim Phase 1/2a results for its RNAi obesity candidates ARO-INHBE and ARO-ALK7. A single 400 mg dose of ARO-INHBE in adults with obesity achieved a mean maximum reduction in serum Activin E of -85%, with a maximum observed reduction of -94%. As monotherapy, ARO-INHBE led by week 16 to a mean visceral fat reduction of -9.9%, a mean liver fat relative reduction of -38%, and an increase in total lean tissue of 3.6%, with two doses at week 24 achieving a -15.6% mean visceral fat reduction adjusted for placebo.
In obese patients with type 2 diabetes on tirzepatide, adding two 400 mg doses of ARO-INHBE roughly doubled weight loss at week 16 (-9.4% vs -4.8%) and produced larger fat reductions, including liver fat relative reduction of -76.7% vs -20%. ARO-INHBE was generally well tolerated, with mostly mild events and one serious limb abscess deemed unrelated. ARO-ALK7 showed adipocyte target silencing with mean adipose ALK7 mRNA reduction of -88% at 200 mg and a -14.1% placebo-adjusted visceral fat reduction at week 8, with a generally favorable safety profile and no serious adverse events.